Company Description
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD).
It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson’s disease for patients with Parkinson’s disease.
The company was incorporated in 2019 and is headquartered in Mountain View, California.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 2, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Amit Etkin |
Contact Details
Address: 650 Castro Street, Suite 450 Mountain View, California 94041 United States | |
| Phone | 650 200 0412 |
| Website | altoneuroscience.com |
Stock Details
| Ticker Symbol | ANRO |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1999480 |
| CUSIP Number | 02157Q109 |
| ISIN Number | US02157Q1094 |
| Employer ID | 83-4210124 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Amit Etkin M.D., Ph.D. | Founder, Chairman of the Board, Chief Executive Officer and President |
| Nicholas C. Smith | Chief Financial Officer and Chief Business Officer |
| Dan Segal B.Sc. (Hons), BCom, CA, MSc | Co-Founder and Strategic Advisor |
| Erin R. McQuade J.D. | General Counsel, Chief Administrative Officer and Corporate Secretary |
| Adam Savitz M.D., Ph.D. | Chief Medical Officer |
| Jessica Powell | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 16, 2026 | 8-K | Current Report |
| Mar 16, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 16, 2026 | 10-K | Annual Report |
| Mar 16, 2026 | 8-K | Current Report |
| Feb 18, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G | Filing |